Retatrutide

Retatrutide (LY3437943) is a novel triple-acting receptor agonist that simultaneously targets three key metabolic receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This first-in-class approach combines the appetite-suppressing and insulin-sensitizing effects of GLP-1 agonism with the metabolic benefits of GIP receptor activation and the energy expenditure and lipolytic effects of glucagon receptor signaling.

Retatrutide activates three complementary metabolic pathways: GLP-1 receptor agonism reduces appetite and slows gastric emptying; GIP receptor activation improves insulin sensitivity; glucagon receptor agonism increases hepatic energy expenditure, promotes lipolysis, and enhances fatty acid oxidation.